Barbadin (C007B-335913)

Barbadin is a novel and selective β-arrestin/β2-adaptin interaction inhibitor, has IC 50 values of 19.1 μM for β-arrestin1 and 15.6 μM for β-arrestin2. Barbadin blocks agonist-promoted endocytosis of the prototypical β2-adrenergic, V2-Vasotocin and angiotensin-II type-1 receptors. Barbadin can induce apoptosisIn VitroBarbadin (4 h) treatment reduces cell viability and induces apoptosis. Barbadin (2 h) treatment arrests breast cancer cells in G0/G1 phase. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Apoptosis AnalysisCell Line: MDA MB-231 cells Concentration: Incubation Time: 4 hours Result: Exhibited morphological characteristics of apoptosis including shrinkage, rounding and detachment, the percent of cell viability was reduced to 69.1% and apoptosis was developed in 29.9% of cells starved with EBSS (Earle’s balanced salt solution). Cell Cycle AnalysisCell Line: MDA MB-231 cells Concentration: Incubation Time: 2 hours Result: Arrested 63.7% of cells in G0/G1 phase.Form:SolidIC50& Target:IC50: 19.1 μM (β-arrestin1),15.6 μM (β-arrestin2). Specification: 0.98 Molecular Formula: C19H15N3OS Molecular Weight: 333.41 PubChem CID: 727640 Isomeric SMILES: C1=CC=C(C=C1)CC2=CC=C(C=C2)C3=CSC4=C3C(=O)N(C=N4)N

UPC:

51113301

Condition:

New

Weight:

1.06 Ounces

HazmatClass:

No

Quantity:

1

Unit of Measurement:

EA

WeightUOM:

LB

MPN:

B647761-2mg

CAS:

356568-70-2

Product Size:

2mg